Sertoz Ayzin Deniz, Ates Orhan, Keles Sadullah, Kocer Ibrahim, Kulacoglu Destan Nil, Baykal Orhan
Atatürk University, Faculty of Medicine, Department of Ophthalmology, Erzurum, Turkey.
Eurasian J Med. 2008 Dec;40(3):103-8.
The aim of this study was to compare the results of monotherapy (photodynamic therapy) and combined therapy (photo-dynamic therapy with posterior sub-Tenon triamcinolone acetonide) in age-related macular degeneration (AMD).
Forty eyes from forty patients with diagnosed neovascular AMD were enrolled in this study during March-2005 - October-2008. All patients were grouped in either the study or the control group. Both the study and control groups consisted of 20 eyes from 20 patients. The study group was treated with posterior sub-Tenon triamcinolone acetonide (PSTA) along with their initial photodynamic therapy (PDT) treatment. The control group members were treated with PDT alone. All patients were examined at 1, 3, 6 and 12 months. Visual acuity (VA), lesion size and number of treatment sessions were recorded during each examination.
The mean difference between pre- and post-treatment VA using the Snellen chart was +0.6 ± 1.7 in study group and -1.4 ± 1.7 in control. The difference for VA was significant in the study group as compared to control (p<0.05). The decrease in lesion size in the study group was 680±1195.2 µm, and the decrease was 32.75 ± 809.9 µm in the control. The difference with regard to the decrease in lesion sizes was significant in the study group as compared to the control (p<0.05). Total PDT treatment sessions were applied 1.2 times per patient in the study group and 1.9 times per patient in the control group. The difference was not significant (p>0.05).
Our study showed that PSTA with PDT significantly reduces CNV growth, and improves VA at the 12-month follow-up in patients with AMD.
本研究旨在比较单药治疗（光动力疗法）与联合治疗（光动力疗法联合后Tenon囊下注射曲安奈德）在年龄相关性黄斑变性（AMD）中的治疗效果。
2005年3月至2008年10月期间，40例确诊为新生血管性AMD的患者的40只眼睛纳入本研究。所有患者被分为研究组或对照组。研究组和对照组均由20例患者的20只眼睛组成。研究组在初始光动力疗法（PDT）治疗的同时接受后Tenon囊下注射曲安奈德（PSTA）治疗。对照组患者仅接受PDT治疗。所有患者在1、3、6和12个月时接受检查。每次检查时记录视力（VA）、病变大小和治疗次数。
使用Snellen视力表，研究组治疗前后VA的平均差异为+0.6±1.7，对照组为-1.4±1.7。与对照组相比，研究组的VA差异具有统计学意义（p<0.05）。研究组病变大小的减小为680±1195.2 µm，对照组为32.75±809.9 µm。与对照组相比，研究组病变大小减小的差异具有统计学意义（p<0.05）。研究组每位患者接受PDT治疗的总次数为1.2次，对照组为1.9次。差异无统计学意义（p>0.05）。
我们的研究表明，PSTA联合PDT可显著减少AMD患者的脉络膜新生血管生长，并在12个月随访时改善视力。
